Call for Abstract

34th World Congress on Vaccines and Immunization, will be organized around the theme Progress and novel strategies in Vaccine Development

Vaccines Congress 2019 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Vaccines Congress 2019

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

  • Track 1-1Animal immunizations
  • Track 1-2Innovations in animal vaccines
  • Track 1-3Livestock animal vaccines and vaccinations
  • Track 1-4Pet vaccines and vaccinations
  • Track 1-5Veterinary vaccines for animals
  • Track 1-6Tetanus, diphtheria, acellular pertussis vaccine during pregnancy
  • Track 1-7Vaccine Administration, Storage & Handling
  • Track 2-1Diphtheria and tetanus toxoids usage in pediatrics
  • Track 2-2Inactivated bacterial vaccines
  • Track 2-3Innovative toxoid vaccine development
  • Track 2-4Live attenuated bacterial vaccinations
  • Track 2-5Maternal immunization
  • Track 3-1Age acceleration effects due to HIV infection
  • Track 3-2Attenuated Virus Vaccines in HIV Infection
  • Track 3-3HIV stems vaccination
  • Track 3-4HIV Vaccine development from Animal Models
  • Track 3-5Microbicides for sexually Transmitted Diseases
  • Track 3-6Recombinant vector vaccine
  • Track 4-1Chickenpox vaccine
  • Track 4-2Diphtheria vaccines
  • Track 4-3Haemophilus influenza type b vaccines
  • Track 4-4Hepatitis A vaccines
  • Track 4-5Hepatitis B vaccines
  • Track 4-6Influenza vaccines
  • Track 4-7MMR vaccines
  • Track 4-8Pneumococcal Vaccine
  • Track 4-9Polio vaccines
  • Track 5-1Cost effective production
  • Track 5-2Vaccines Awareness
  • Track 5-3Vaccines Investments and partnerships
  • Track 5-4Vaccines Marketing
  • Track 6-1Contraindications - Vaccines, vaccination
  • Track 6-2New approaches to combat bacterial pathogens
  • Track 6-3Public health concerns in vaccination
  • Track 6-4Vaccine resistance and need of Next-Gen Conjugate Vaccines
  • Track 6-5Vaccines formulation and technologies used in conjugated vaccines
  • Track 7-1Biotherapeutics
  • Track 7-2Purified subunit vaccines
  • Track 7-3Recombinant subunit vaccine
  • Track 7-4Vaccines under research
  • Track 8-1Decreases in disease risks and increased attention on vaccine risks.
  • Track 8-2Vaccine Safety Monitoring and Vaccine Pharmacovigilance
  • Track 8-3Vaccine safety communication
  • Track 8-4Public confidence in vaccine safety is critical
  • Track 8-5Post marketing surveillance of Vaccines
  • Track 8-6Patient and Public acceptance and perceptions
  • Track 8-7Higher standard of safety is expected of vaccines
  • Track 8-8Factors Influencing Vaccine efficacy
  • Track 8-9Factors Influencing Vaccine efficacy
  • Track 8-10Vaccines generally healthy (vs. ill for drugs)
  • Track 9-1Contraindications and precautions during vaccination in geriatrics
  • Track 9-2Flu shots for seniors
  • Track 9-3Herpes zoster vaccines
  • Track 9-4Immunization and its side effects in geriatrics
  • Track 9-5Immunization schedule for elderly people
  • Track 9-6Pneumococcal polysaccharide vaccines
  • Track 9-7Risk factors in geriatric immunization
  • Track 9-8Vaccine dosing and administration in older adults
  • Track 10-1Anthrax and Smallpox
  • Track 10-2Ebola, Marburg, Lassa, and Machupo Virus
  • Track 10-3Nipah virus
  • Track 10-4Plague and Tularemia
  • Track 10-5Q fever, Ricin toxin, Typhus fever
  • Track 11-1Age-specific Immune Response to Vaccination
  • Track 11-2Immunology / Animal Models
  • Track 11-3Novel Approaches in Design of Cellular and Molecular-Based Vaccines
  • Track 11-4Plant Based Vaccines & Combination Vaccines
  • Track 11-5Therapeutic Vaccination for Auto Immune Diseases
  • Track 11-6Vaccination in Pregnancy, New-borns and the Elderly populations
  • Track 11-7Vaccines against Vector-borne Diseases
  • Track 11-8Vaccines Related to Human Reproduction and Fertility Control
  • Track 12-1Antibody-targeted fusion proteins for Cancer Therapy
  • Track 12-2Autoimmunity & Biotechnology
  • Track 12-3Clinical Laboratory Immunology
  • Track 12-4Immune-mediated Neurological Syndromes
  • Track 12-5Immunological aspects of Endocrine diseases & Chronic diseases
  • Track 12-6Immunological aspects of infection
  • Track 12-7Monoclonal antibodies and Organ Cancers
  • Track 12-8Tumor Immunology and Immunotherapy
  • Track 13-1Allergies and skin diseases in Traveller - Vaccinations
  • Track 13-2Challenges in implementing Immunization programs and Improvement strat
  • Track 13-3Health Considerations for Adventure Travel
  • Track 13-4Immunization in Immunocompromised patients
  • Track 13-5Travel immunizations and Safety issues
  • Track 14-1DNA vaccines against HIV/AIDS
  • Track 14-2Endogenous vaccinations
  • Track 14-3Exogenous vaccinations
  • Track 14-4MHC Classes
  • Track 14-5Plasmid DNA Vaccinations
  • Track 14-6Recombinant DNA Technology
  • Track 15-1Antiviral therapy-Immune system
  • Track 15-2Current advanced research on HPV
  • Track 15-3Hepatitis Viruses & Co-infection with HIV
  • Track 15-4HPV & Hepatitis Vaccines Current Updates
  • Track 15-5HPV Infection & Cancer
  • Track 15-6HPV Vaccines Safety, Prevention
  • Track 16-1Advances in DNA Vaccines, TLRS and Combination Adjuvants
  • Track 16-2Latest techniques and advancements in Vaccine delivery systems
  • Track 16-3Nano patch Technologies
  • Track 16-4Needle-free vaccine delivery
  • Track 16-5Routes & Medical devices for vaccines delivery
  • Track 16-6Transdermal Delivery of Vaccines
  • Track 16-7Vehicle, Mineral Salt & Bacteria Derived Adjuvants
  • Track 17-1Current Challenges in Vaccine R & D
  • Track 17-2Current Focus in Virology Research
  • Track 17-3Regulatory and Economical Aspects in Virology
  • Track 17-4Viral Genomics and Proteomics
  • Track 18-1Attenuated vaccine
  • Track 18-2Inactivated vaccine
  • Track 18-3Rotavirus
  • Track 18-4Rubella virus
  • Track 18-5Varicella zoster virus
  • Track 18-6Virus- Particles as vaccines, vectors and adjutants
  • Track 19-1Antibodies and neuroscience
  • Track 19-2Antibodies as drugs: Immunological scaffolds as therapeutics
  • Track 19-3Antibody biology & engineering
  • Track 19-4Genetics and epigenetics of the immune system
  • Track 19-5Non antibody immunity
  • Track 20-1Chiropractic vaccination care in women and pregnancy
  • Track 20-2Halting vaccination in pregnancy
  • Track 20-3HIV and other STD vaccines for pregnant women
  • Track 20-4HPB, HAV, HBV vaccination for neonates
  • Track 20-5Immunization during or before pregnancy / delivery
  • Track 20-6Influenza vaccination of pregnant women and protection of their infants
  • Track 20-7Whooping Cough vaccines in pregnant women
  • Track 21-1Central nervous system-targeted & Tissue-specific autoimmunity
  • Track 21-2Innate immunity and diabetes vaccines
  • Track 21-3Vaccination strategy in patients with IMID
  • Track 21-4Vaccine safety: impact on disease activity in IMID patients
  • Track 21-5Vaccines for autoimmune skin disorders & neuropathies
  • Track 21-6Vaccines for immunodeficiency diseases
  • Track 22-1Helminthiasis
  • Track 22-2Progress and challenges
  • Track 22-3Protozoa
  • Track 22-4Viruses
  • Track 23-1Bordetella vaccines
  • Track 23-2Chickenpox Vaccine & Measles Vaccines
  • Track 23-3Ebola Outbreak & Tuberculosis Vaccines
  • Track 23-4Emerging, Re-Emerging & Communicable Diseases
  • Track 23-5Meningococcal /Menactra Vaccines
  • Track 23-6Mucosal & Edible Vaccines
  • Track 23-7Pneumonia Vaccines
  • Track 23-8Rotavirus & Smallpox Vaccines
  • Track 24-1Personalized Medicine
  • Track 24-2Recent focus in Virology
  • Track 24-3Regulatory/societal/economic/programmatic and legislation subjects
  • Track 24-4Retroviral Diseases in Asia, Africa & Middle East
  • Track 24-5Vaccines Bioprocessing & Manufacturing
  • Track 24-6Vectors / adjuvants / drug delivery
  • Track 25-1Allergic reactions
  • Track 25-2Animal derived vaccines
  • Track 25-3Biotherapeutics
  • Track 25-4Development of Plant vaccines-Support
  • Track 25-5Hypersensitivity
  • Track 26-1Latest Innovations in vaccine
  • Track 26-2Live, attenuated, inactivated
  • Track 26-3New Vaccines